Clinical Trials on Invasive Bladder Cancer in Taiwan

Total 1793 results

CG Oncology, Inc.

Recruiting

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin (BOND-003)

Non Muscle Invasive Bladder Cancer | High-grade Ta/ T1 Papillary Disease Bladder Cancer

United States, Korea, Republic of, Taiwan, Japan, Australia
National Cancer Institute (NCI)

Recruiting

Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Bladder Urothelial Carcinoma In Situ | Stage 0a Bladder Cancer AJCC v8 | Stage 0is Bladder Cancer AJCC v8 | Stage I Bladder Cancer AJCC v8 | Invasive Bladder Mixed Carcinoma

United States, Guam, Puerto Rico
Merck Sharp & Dohme LLC

Recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

High-risk Non-muscle Invasive Bladder Cancer

Canada, Belgium, United States, Australia, Austria, France, Germany, Greece, Hungary, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, Peru, Poland, Portugal, Spain, Switzerland, Turkey, United Kingdom, China, Brazil, Colombia, ... and more
Janssen Research & Development, LLC

Recruiting

A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) (SunRISe-3)

Bladder Cancer

United States, Belgium, Korea, Republic of, Italy, Taiwan, China, United Kingdom, Germany, France, Argentina, Brazil, Poland, Spain, Czechia, Japan, Netherlands, India, Canada, Mexico, Australia, Portugal
AstraZeneca

Active, not recruiting

Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC (NIAGARA)

Muscle Invasive Bladder Cancer

United States, Belgium, France, Germany, Italy, Spain, United Kingdom, Canada, Poland, Taiwan, Vietnam, Turkey, Korea, Republic of, Brazil, Czechia, Japan, Philippines, Israel, Chile, Australia, Netherlands, Russian Federation
AstraZeneca

Recruiting

Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin (VOLGA)

Muscle Invasive Bladder Cancer

Netherlands, United Kingdom, Korea, Republic of, Canada, Germany, Italy, Poland, Spain, Turkey, Vietnam, Argentina, Japan, France, Brazil, Taiwan, United States, Israel, Austria, Chile, Colombia, Greece, Hong Kong, Mexico, Portugal, Russian... and more
Bristol-Myers Squibb
Nektar Therapeutics

Completed

A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer

Bladder Cancer | Bladder Tumor | Muscle-Invasive Bladder Cancer

Russian Federation, China, Germany, Italy, United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Czechia, France, Greece, Israel, Mexico, Netherlands, Poland, Spain, United Kingdom
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Active, not recruiting

A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

Urinary Bladder Neoplasms | Muscle-Invasive Bladder Cancer

Russian Federation, United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, Finland, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Mexico, Netherlands, New Zealand, Norway, Portugal, Roman... and more
Janssen Research & Development, LLC

Active, not recruiting

A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

Urinary Bladder Neoplasms

United States, Japan, China, Korea, Republic of, France, Belgium, Czechia, Taiwan, Italy, Poland, United Kingdom, Spain, Germany, Australia, Brazil, Argentina, India
Yung Shin Pharm. Ind. Co., Ltd.

Completed

Evaluate Bioequivalence of Micafungin (50mg/Vial)

Invasive Candidiasis

Taiwan
National Taiwan University Hospital
National Taiwan University

Recruiting

Impacts and Testing of the "Multi-domains Active-living Program" in Operable Non-Muscle Invasive Bladder Cancer Patients

Quality of Life | Bladder Cancer

Taiwan
Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical...

Enrolling by invitation

JING SI HERBAL TEA and Urinary Tract Symptoms in Bladder Cancer

Lower Urinary Tract Symptoms | Bladder Cancer | Intravenous Drug Usage | Herbal Interaction

Taiwan
Astellas Pharma Inc
Astellas Pharma Taiwan, Inc.

Completed

Micafungin Versus Fluconazole in the Treatment of Invasive Candidiasis and Candidemia

Candidemia | Invasive Candidiasis

Taiwan
National Taiwan University Hospital

Completed

Comparisons of the Effects of Solifenacin Versus Mirabegron on Autonomic System, Arterial Stiffness and Psychosomatic Distress and Clinical Outcomes

Overactive Bladder Syndrome

Taiwan
National Taiwan University Hospital

Unknown

Comparisons of 3-month Versus 6-month Solifenacin Treatment for Female OAB Patients

Overactive Bladder Syndrome

Taiwan
National Taiwan University Hospital

Unknown

Post-treatment Novmalized Urodynamiz Findings as the Golden Standard of Objective Cure for Female Overactive Bladder Patients Receiving Antimuscarinic Drug

Overactive Bladder Syndrome

Taiwan
Chung Shan Medical University

Enrolling by invitation

AI Determine Malignancy of GGO on Chest CT

Lung Nodules, Early Lung Cancer, Artificial Intelligence, Chest CT, Minimally Invasive Surgery, Lung Image Analysis Software

Taiwan
National Cancer Institute (NCI)

Recruiting

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Stage IV Renal Cell Cancer AJCC v8 | Sarcomatoid Renal Cell Carcinoma | Stage IV Bladder Cancer AJCC v8 | Stage IV Urethral Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Bladder Adenocarcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Collecting Duct Carcinoma | Bladder... and other conditions

United States, Puerto Rico
Buddhist Tzu Chi General Hospital

Unknown

Therapeutic Efficacy and Safety of Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan

Overactive Bladder Syndrome

Taiwan
Kaohsiung Medical University Chung-Ho Memorial...

Unknown

Bladder Irrigation 0.05% Lidocaine Decreases Postoperative CRBD

Bladder Discomfort

Taiwan
National Taiwan University Hospital

Completed

Bladder Diary for Diagnosing Bladder Oversensitivity

Bladder Oversensitivity

Taiwan
Buddhist Tzu Chi General Hospital

Unknown

Comparison of Solifenacin and Mirabegron in Treatment of Overactive Bladder Symptoms in Men After TURP

Overactive Bladder Syndrome

Taiwan
Chung Shan Medical University

Unknown

Efficacy of Different Electrical Stimulation Placement in Patients With Overactive Bladder Syndrome

Overactive Bladder Syndrome

Taiwan
TaiRx, Inc.

Completed

Safety and Pharmacokinetic Study of TRX-818 in Asian Solid Tumor Patients

Carcinoma | Advanced Cancer

Taiwan
National Cheng-Kung University Hospital

Completed

Sigmoid Colon Organ Motion in Radiotherapy

Sigmoid Colon Cancer | Sigmoid Cancer

Taiwan
Rise Biopharmaceuticals, Inc.
T-TOP Clinical Research Co., Ltd.

Recruiting

RP72 Monotherapy and in Combination With Gemcitabine in Patients With Pancreatic Cancer

Pancreatic Cancer | Pancreatic Cancer Metastatic | Pancreatic Cancer Non-resectable

Taiwan
National Taiwan University Hospital

Completed

Predictors for Retreatement of OAB After DC Mirabegron

Recurrence of Overactive Bladder Syndrome

Taiwan
Standard Chem. & Pharm. Co., Ltd.

Terminated

Safety, Tolerability and Pharmacokinetics of DCBCI0901 in Patients With Advanced Solid Tumor

Cancer

Taiwan
National Health Research Institutes, Taiwan
National Cheng-Kung University Hospital

Recruiting

Genomics and Prognosis in GI Cancers

Liver Cancer | GI Cancer

Taiwan
Taipei Veterans General Hospital, Taiwan

Recruiting

Sequencing and Combination of Mirabegron and TTNS in Overactive Bladder Syndrome: a Multicenter, Randomized, Open-label, Crossover Trial

Overactive Bladder Syndrome

Taiwan
Buddhist Tzu Chi General Hospital

Completed

Flexibly adding-on Second Antimuscarinic Agent to the First Antimuscarinics for Refractory Overactive Bladder Syndrome

Overactive Bladder

Taiwan
National Taiwan University Hospital

Terminated

Physical Therapy for Overactive Bladder

Overactive Bladder

Taiwan
Taipei Medical University WanFang Hospital

Completed

Study and Analysis of Micafungin for Non-albican Candidemia: Efficacy, Risk Factor and Clinical Manifestation

Non-albicans Candidemia

Taiwan
Taipei Medical University Shuang Ho Hospital

Completed

Effect of Ureteral Stents Length and Location on Related Symptom

Lower Urinary Tract Symptoms | Overactive Bladder Syndrome

Taiwan
Chang Gung Memorial Hospital

Unknown

The Clinical Effects of Laser Acupuncture Therapy for OAB Women.

Overactive Bladder

Taiwan
Buddhist Tzu Chi General Hospital

Completed

Different Injection Number of the Same Dose of Botulinum Toxin A on Overactive Bladder Syndrome

Overactive Bladder

Taiwan
Buddhist Tzu Chi General Hospital

Completed

Effects and Safety of Liposome Encapsulated Botulinum Toxin A for Overactive Bladder Syndrome

Overactive Bladder

Taiwan
Buddhist Tzu Chi General Hospital

Completed

Antimuscarinics as the First-line Treatment for Male With IPSS-V/S≤1

Bladder Outlet Obstruction

Taiwan
TaiRx, Inc.

Completed

Safety and Pharmacokinetic Study of CVM-1118 Extended-Release in Advanced Cancer Patients

Advanced Cancer

Taiwan
National Cheng-Kung University Hospital
National Cheng Kung University

Recruiting

Physical Training for Elderly Cancer Patients With Cachexia (TEECH-01)

Cancer | Cancer Cachexia | Geriatric Assessment

Taiwan
National Cheng-Kung University Hospital

Unknown

Thalidomide and Tegafur/Uracil(UFUR) in the Treatment of Advanced Colorectal Cancer (UFUR)

Colon Cancer

Taiwan
National Taiwan University Hospital

Completed

Studies of Psychiatric Predisposing Factors, Treatment-related Cardiovascular Effects, and Prognostic Factors Associated With Antimuscarinic Drug (Tolterodine) for Female Overactive Bladder Syndrome

Antimuscarinic Drug

Taiwan
PharmaEngine

Completed

Phase I and Pharmacokinetic Study of Biweekly PEP02 in mCRC Refractory to 1st-line Oxaliplatin Base Therapy

Metastatic Colorectal Cancer

Taiwan
Far Eastern Memorial Hospital

Completed

Medical Records Investigation of Whether Perioperative Dexmedetomidine Will Reduce the Duration of Mechanical Ventilation or Hospital Length of Stay in Patients Undergoing Minimally Invasive Cardiac Surgery

Mechanical Ventilation | Hospital Length of Stay | Minimally Invasive Cardiac Surgery

Taiwan
Taipei Medical University WanFang Hospital

Unknown

The Relationship Between Morphology and Virulent Genes of Candida Albicans and Clinical Aspects, Surveillance of Fungemia

Candidemia Prognostic Factor and Mycobiological Analysis.

Taiwan
National Cheng-Kung University Hospital

Terminated

Metformin in Stage IV Lung Adenocarcinoma

Non-small Cell Lung Cancer

Taiwan
Far Eastern Memorial Hospital

Recruiting

Predictors Affecting Long-term Use of Solifenacin or Mirabegron in Women With Overactive Bladder Syndrome

Overactive Bladder Syndrome

Taiwan
Far Eastern Memorial Hospital

Recruiting

Mirabegron for Female OAB Patients: Comparison of Daytime and Nighttime Dosing

Overactive Bladder Syndrome

Taiwan
Far Eastern Memorial Hospital

Withdrawn

Impact of Beta-3 Agonist on Psychological Distress and Blood Flow of the Bladder in Women With Overactive Bladder Syndrome

Overactive Bladder Syndrome

Taiwan
National Taiwan University Hospital

Completed

DU and BOO in Women With and Without Symptoms of VD

Bladder Outlet Obstruction | Detrusor Underactivity

Taiwan

Clinical Trials on Invasive Bladder Cancer in Taiwan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations